In TP53-mutated AML patients, AZA was shown to yield a 20–30% CR rate and a median OS at 7 months [36]; and DAC a 20–30% CR rate and a median OS of 6–12 months [37,38,39,40]. This evidence concerns the gene TP53 and acute myeloid leukemia.